Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
FDMT
SELL4D Molecular Therapeutics, Inc. · Healthcare · United States · $526M · Avg Vol: $10M/d
COMPANY DESCRIPTION
4D Molecular Therapeutics is a clinical-stage gene therapy company developing precision AAV vector-based therapeutics for genetic diseases across ophthalmology, pulmonology, and cardiology. Its proprietary Therapeutic Vector Evolution platform allows for the engineering of optimized AAV vectors with enhanced tropism, immunogenicity, and efficiency. This positions FDMT as a specialized innovator in the gene therapy space, aiming to overcome limitations of conventional gene delivery.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 18.0M | 3.1M | 20.7M | 37.0K | 85.2M | 47.4% | 88.2M | 11.6M | 17.5M | -54.7% |
| EPS | -2.57 | -3.32 | -2.58 | -2.98 | -2.42 | — | -2.59 | -3.93 | -3.77 | — |
| Shares | 32.2M | 32.6M | 43.1M | 45.8M | 57.6M | +78.8% | 52.3M | — | — | — |
| Debt | 16.4M | 16.1M | 14.7M | 24.6M | 21.4M | 6.8% | 20.5M | — | — | — |
| Equity | 319.1M | 231.3M | 307.8M | 510.6M | 505.7M | 12.2% | — | — | — | — |
| Op CF | -69.1M | -86.7M | -75.8M | -134.6M | -109.1M | — | -129.4M | — | — | — |
| Inv CF | -172.7M | -17.1M | 115.7M | -302.4M | -93.0M | — | — | — | — | — |
| Fin CF | 118.1M | 3.1M | 156.8M | 337.3M | 113.0M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of FDMT are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| FDMT | 4D Molecular Therapeutics, Inc.(you) | $526M | 28 | SELL |
| ARTV | Artiva Biotherapeutics, Inc. | $487M | 26 | SELL |
| CBIO | Crescent Biopharma, Inc. | $602M | 26 | SELL |
| SGMT | Sagimet Biosciences Inc. | $437M | 30 | SELL |
| ASMB | Assembly Biosciences, Inc. | $506M | 23 | SELL |
| IMMX | Immix Biopharma, Inc. | $607M | 31 | SELL |
| NVCT | Nuvectis Pharma, Inc. | $609M | 25 | SELL |
| TENX | Tenax Therapeutics, Inc. | $385M | 28 | SELL |
| PRTC.L | PureTech Health plc | $421M | 26 | SELL |
| RZLT | Rezolute, Inc. | $480M | 23 | SELL |
Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.6%